Five BSE Midcap Stocks Hit 52-Week Highs With Gains of Up to 18% in a Single Month

The Quick Take

• KEI Industries, GSK Pharma, Lenskart, Radico Khaitan, and Ajanta Pharma all reached fresh 52-week highs.
• The five stocks recorded gains of up to 18% over the past month, outpacing the broader midcap index.
• Diverse sector representation — cables, pharma, consumer, and beverages — signals broad midcap momentum.

Five BSE Midcap constituents — KEI Industries, GSK Pharmaceuticals, Lenskart Solutions, Radico Khaitan, and Ajanta Pharma — simultaneously hit fresh 52-week highs this week, each logging gains of up to 18% over the trailing month. The cluster spans diverse sectors including electrical cables, pharmaceuticals, eyewear retail, spirits, and specialty pharma, suggesting the midcap momentum is not sector-specific.

KEI Industries has benefited from the power infrastructure capex cycle, while GSK Pharma and Ajanta Pharma reflect renewed investor confidence in domestic formulation plays. Radico Khaitan, a premium spirits brand, has seen volume recovery, and Lenskart continues to ride its omnichannel retail expansion story. The convergence of these names at multi-month highs underscores broader risk appetite in the BSE Midcap universe.

BSE Midcap stocks have historically outperformed large-caps during phases of broad domestic economic confidence and stable rupee. With FII inflows stabilizing and domestic institutional investors continuing to deploy SIP capital, the structural support for quality midcaps remains intact. Investors will watch whether these 52-week high crossovers attract further momentum buying or trigger profit-taking at resistance levels.

Synthesized from 1 source.